GlassScriptPhysician profile
Jaime G Pugeda
NPI 1639153281
$1,206.38
in general payments reported to CMS, 2019-2025
15 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $281 · 2021: $285 · 2022: $79.21 · 2023: $47.17 · 2024: $94.36 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $289.78 | 2019-2021 | |
| Abiomed | $233.52 | 2019-2020 | |
| Penumbra, INC. | $168.90 | 2019-2025 | Penumbra System |
| Shockwave Medical, INC | $99.63 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $75.30 | 2020-2023 | Xarelto |
| Amgen INC. | $72.01 | 2024-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $67.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $65.54 | 2024-2025 | |
| Cardiva Medical, INC. | $24.10 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Teleflex LLC | $23.92 | 2022 | |
| Angiodynamics, INC. | $23.46 | 2025 | Alphavac |
| Regeneron Healthcare Solutions, INC. | $20.10 | 2019 | |
| Abbott Laboratories | $15.95 | 2023 | Diamondback Coronary |
| Cardiovascular Systems INC. | $14.24 | 2023 | Diamondback Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Pugeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.